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ABSTRACT 
Reference treatment of advanced prostate cancer (PCa) relies on pharmacological or surgical 
androgen deprivation therapy. However, it is only temporarily efficient as tumour cells inevitably 
adapt to the low testosterone environment and become hormone-refractory (HRPCa). We observed 
that androgen removal in HRPCa-derived LNCaP cells causes different alterations in their Ca2+ 
homeostasis among which a reduction of ER Ca2+ content. We show that the decrease in [Ca2+]ER is 
due to a modest overexpression of type 1 IP3R and a 3-fold increased phosphorylation of IP3R1 on 
Ser-1716, a protein kinase A (PKA) consensus site, both implicated in ER Ca2+ leak. Accordingly, 
ER Ca2+ content was restored by siRNA-mediated down-regulation of IP3R1 or by inhibition of its 
phosphorylation by competition with a permeant TAT-peptide containing the Ser-1716 consensus 
phosphorylation sequence or by treatment with the PKA inhibitor H89. Moreover, inhibition of the 
IP3R1 phosphorylation by both methods sensitized the LNCaP cells to androgen deprivation-
induced apoptosis. In addition, SERCA2b overexpression precluded the effect of androgen 
deprivation on ER Ca2+ store content and reduced resistance to androgen deprivation. Taken 
together, these results indicate that lowering the ER Ca2+-store content by increasing IP3R1 levels 
and IP3R1 phosphorylation by PKA is a protective mechanism by which HRPCa-derived cells 
escape cell death in the absence of androgenic stimulation. 
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INTRODUCTION 
Metastatic prostate cancer (PCa) is associated with a poor prognosis with a 5-year relative survival 
of 27% [1]. Reference treatment of metastatic PCa consists in pharmacological or surgical androgen 
deprivation therapy. However, androgen deprivation is only temporarily efficient. After a few 
months or years, the tumor inevitably relapses despite the absence of androgenic stimulation and 
becomes hormone-refractory (HRPCa). Effective treatment at this stage is largely limited to 
docetaxel-based chemotherapies conferring a median survival of only 17 to 19 months [2, 3]. 
Among commercially available HRPCa cell lines, only LNCaP cells harbor the androgen receptor 
(AR) [4].  
The role of Ca2+ in prostate involution induced by androgen deprivation (AD) has been recognized 
for more than two decades [5]. Mitochondrial membrane permeabilization (MMP) constitutes a key 
event in apoptotic cell death [6]. At least, two mechanisms can enhance the Ca2+ transfer between 
ER and mitochondria. On the one hand, this could be related to an increase in Ca2+ conductance 
between ER and mitochondria after apoptosis induction. Indeed, it has been proposed that excessive 
transfer of Ca2+ from the ER to the mitochondria possibly through a protein complex comprising the 
inositol trisphosphate receptor, the glucose-regulated protein 75 and the voltage-dependent anion 
channel (IP3R/grp75/VDAC) [7] via MMP induction, release of intermembrane proapoptotic 
factors, dissipation of mitochondrial transmembrane potential (ΔΨm), formation of apoptosomes 
and subsequent cell death [8, 9]. Thus, overactivation/overexpression of one member of the 
IP3R/grp75/VDAC complex could enhance the sensitivity to proapoptotic agents. On the other 
hand, the ER-mitochondria Ca2+ flux might be enhanced by an increase in the electrochemical 
gradient e.g. subsequently to an increase in [Ca2+]ER. Indeed, antiapoptotic proteins such as Bcl-2 or 
Bcl-XL decrease [Ca2+]ER whereas proapoptotic proteins such as Bax or Bak have the opposite 
effect, at least in some cell systems [10]. This suggests that [Ca2+]ER is closely related to the 
sensitivity to cytotoxic stimuli [11]. Increase in [Ca2+]ER can be secondary to an increase in the ER 
refilling, e.g. due to an increase in SERCA activity or expression, or to a decrease in Ca2+ leak from 
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ER. In mouse embryonic fibroblasts, the group of Korsmeyer showed several years ago that IP3R1 
constituted an ER Ca2+ leak channel, the permeability of which was modulated by a protein kinase 
A (PKA)-mediated phosphorylation, itself increased by Bcl-2 and decreased by Bax or Bak 
expression [12]. In T-lymphocytes however Bcl-2 can dock both DARPP-32 and calcineurin to the 
IP3R, whereby the PKA-mediated phosphorylation of the latter is antagonized, leading to decreased 
IP3R-mediated Ca2+ release [13]. Very recently, in an siRNA screen for the identification of ER 
Ca2+-leak channels, IP3R1 channels emerged as one of the most prominent Ca2+-transport systems 
implicated in ER Ca2+ leak [14]. 
In the present study, we show that AD decreases [Ca2+]ER in LNCaP cells and suggest that this is 
mediated by a phosphorylation-dependent increase in IP3R1 permeability. Inhibition of IP3R1 
phosphorylation restores LNCaP cells sensitivity to AD and could be a novel therapeutic target for 
the treatment of HRPCa. 
 
RESULTS 
Androgen deprivation alters intracellular Ca2+ homeostasis 
In order to study the effects of AD on [Ca2+]c and on [Ca2+]ER, we measured [Ca2+]c in LNCaP cells 
cultured in the absence or in the presence of synthetic androgen R1881 for 48 h. Fura-2 loaded cells 
were treated with the SERCA inhibitor thapsigargin in the absence of external Ca2+ and then, Ca2+ 
was reintroduced in the external medium to evaluate the amplitude of store-operated Ca2+ entry 
(SOCE). We observed that AD had no effect on [Ca2+]c but reduced by about 40% the amount of 
thapsigargin-induced Ca2+ release, suggesting a decrease of the ER Ca2+ store content. SOCE was 
also decreased after AD (Fig. 1A and B). Interestingly, treatment of the cells with the AR specific 
inhibitor bicalutamide (50 µM) for 48 hours also decreased releasable Ca2+ from the ER (data not 
shown). We also observed that basal influx of Ca2+ through the plasma membrane as measured by 
the Mn2+-induced Fura-2 quenching technique was diminished after androgen removal (Fig. 1C). 
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We therefore tried to decipher the mechanisms underlying these modifications and measured the 
expression of a series of proteins possibly involved in Ca2+ homeostasis (Ca2+ pumps, channels and 
buffers). AD induced a strong decrease in TRPM8 expression and a more than 2-fold increase in 
IP3R1 expression at the mRNA level (Fig. 2). Previous studies have shown that the expression of 
the Ca2+ channel TRPM8 is highly dependent on the presence of androgens and is overexpressed in 
prostate cancer cells [15, 16]. Its repression after androgen removal might therefore explain 
alterations in Ca2+ homeostasis. IP3R1 beside its well-known role in agonist-induced Ca2+ 
signaling, might also function as an ER Ca2+ leak channel [12, 17], thereby controlling resting 
[Ca2+]ER. Importantly, its activity has been reported to be phosphorylation-dependent [18]. 
 
Involvement of TRPM8 in Ca2+ homeostasis alterations induced by AD 
Given the importance of AD on TRPM8 expression, we tried to mimic this effect by depleting 
TRPM8 in LNCaP cells using specific siRNA. The silencing of TRPM8 was proved by RT-qPCR 
(Fig. 3A) and was correlated with a significant decrease of basal influx of Ca2+ (Fig. 3C). This 
indicates that the channel is expressed, at least partially, at the plasma membrane and that the 
decrease of its expression due to AD could be responsible for basal Ca2+ influx reduction. However, 
we did not observe any subsequent decrease in [Ca2+]c, in thapsigargin-evoked Ca2+ release or in 
SOCE (Fig. 3B). 
 
Involvement of IP3R1 in Ca2+ homeostasis alterations induced by AD 
It has been suggested that IP3R1 could control resting [Ca2+]ER [12, 14]. After AD treatment in 
LNCaP cells, we observed a modest increase in the amount of IP3R1 protein (Fig. 4A and B) and a 
dramatic increase in IP3R1 phosphorylation on the PKA consensus site Ser-1716 (equivalent to Ser-
1756 in the rat IP3R1 amino acid sequence). Incidentally, IP3R2 was not expressed in LNCaP cells 
[19] and expression of IP3R3 mRNA was not modified by AD (Fig. 2). 
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In order to evaluate the effects of IP3R1 phosphorylation and expression on [Ca2+]ER, we first 
measured the Ca2+ content in the ER after inhibition of PKA-mediated IP3R1 phosphorylation. As 
also performed in Fig. 1, we tried to evaluate [Ca2+]ER after thapsigargin treatment. However, we 
observed that acute inhibition (5 minutes pretreatement) of IP3R by xestospongin B decreased by 
itself the amount of releasable Ca2+ (Fig. 5A). This suggested that IP3R is the Ca2+ leak channel in 
thapsigargin-induced ER depletion. Since we were interested in the permeability of IP3R, a 
procedure using thapsigargin to evaluate [Ca2+]ER was obviously inadequate. We then decided to use 
ionomycin to permeabilize the ER membrane and measure releasable Ca2+ independently of the 
IP3R-mediated leak. We observed that the ionomycin-induced Ca2+ release was decreased by AD 
(Fig. 5E and F), confirming the results obtained with thapsigargin (Fig. 1B). We then interfered 
with IP3R1 phosphorylation by using a cell-permeable TAT-peptide (TAT-IP3R1S1716) containing 
the Ser-1716 consensus phosphorylation sequence. AD-induced phosphorylation of IP3R1 was 
abolished after treatment with 80 µM TAT-IP3R1S1716 (Fig. 5B and C). As Ser-1716 is known to be 
phosphorylated by PKA [20, 21], we treated LNCaP cells with H89, a selective inhibitor of this 
kinase. We observed that 10 µM H89 treatment strongly reduced IP3R1 phosphorylation (Fig. 5B 
and 5D). This effect was stronger than that observed with TAT-IP3R1S1716 treatment and occurred 
even in the presence of androgen. In the presence of 80 µM TAT-IP3R1S1716, the effect of AD on 
ionomycin-induced Ca2+ release was abolished (Fig. 5E). Inhibition of PKA by H89 strongly 
increased [Ca2+]ER and also inhibited AD-induced decrease in [Ca2+]ER (Fig. 5F).  
 
Involvement of IP3R1 phosphorylation in the resistance to AD 
The results presented above suggest that the decrease in [Ca2+]ER is due to an increase of the amount 
of  IP3R1 phosphorylated on its serine 1716 residue consecutively to AD. We therefore investigated 
whether this process was involved in the resistance of LNCaP cells to AD. LNCaP cells were 
treated for 72h with 80 µM TAT-IP3R1S1716 in the presence or in the absence of androgen. 
Simultaneous fluorimetric detection of mitochondrial membrane potential (ΔΨm) dissipation and 
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plasma membrane permeabilization, two markers associated with cell death, showed that TAT-
IP3R1S1716 strongly sensitized LNCaP cells to AD (Fig. 6A and B). TAT-IP3R1S1716 did however 
not exert any effect on cell death in the presence of androgen. 
Additionally, we observed that 10 µM H89 also restored AD-dependent cell death but did not affect 
cell viability in the presence of androgen (Fig. 6C and D). Its effect on AD-dependent cell death 
was strongly diminished by adding 0.5 µM thapsigargin during the last 24 hours of AD treatment. 
This suggests that the inhibition of PKA by H89 exerts its effect on cell death by modulating 
[Ca2+]ER. 
To confirm the role of Ca2+ store in the resistance to AD, we partially prevented AD-induced Ca2+ 
store depletion by overexpressing SERCA2b, the isoform the most ubiquitously expressed in non-
muscle tissues (Fig. 7A) and measured the effects of such [Ca2+]ER stabilization on cell survival. We 
observed that SERCA2b overexpression increased the proportion of apoptotic cells after AD 
treatment proving ER Ca2+ store control on LNCaP sensitivity to AD (Fig. 7B). 
 
Effects of IP3R1 phosphorylation on autophagy  
We previously showed that AD induces autophagy in LNCaP cells and that genetic or 
pharmacological inhibition of autophagy also restores AD-dependent cell death [22]. Furthermore, 
IP3Rs and downstream Ca2+ signaling have been implicated in mTOR-controlled autophagy [23, 
24]. We therefore studied here whether AD-induced [Ca2+]ER modulation was involved in 
autophagy.  
Upon autophagy induction, the LC3-I protein is modified into the lipidated form, LC3-II. This latter 
is associated with autophagosomes and its detection is routinely used to monitor autophagy [25]. 
We observed that LC3-II levels declined after AD (Fig. 8A and B). To distinguish whether this 
observation was due to a decrease in the on-rate of autophagic LC3-II formation or an increase in 
the off-rate of, the lysosomal LC3-II degradation, we used a combination of E64d and pepstatin A  
to inhibit lysosomal function and block LC3-II degradation. The use of inhibitors revealed that 
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LC3-II was increased, demonstrating that AD promotes autophagy at the level of the 
autophagosomal/lysosomal fusion and/or degradation events. Together, these observations confirm 
our previous study showing that AD increases autophagic rate in LNCaP cells [22]. 
H89 treatment did not preclude AD-induced LC3-II degradation, suggesting that phosphorylation of 
IP3R1 is not responsible for the AD-induced autophagy flux at the level of 
autophagosomes/lysosomes (Fig. 8A and B). These results were corroborated by detection of 
another biochemical sign of autophagy, namely the redistribution of GFP-LC3 fusion protein from a 
ubiquitous, diffuse pattern towards autophagosomes, which became visible as cytoplasmic puncta, 
independently of the presence of H89 (Fig. 8C). 
Consistent with these findings, genetic inhibition of autophagy by siRNA-mediated depletion of the 
essential autophagy gene product Atg5 did not modify AD-induced decrease of the thapsigargin-
releasable pool of Ca2+ (Fig. 8D). This suggests that the effects of AD on Ca2+ stores were not due 
to an autophagic degradation of ER membranes or ER proteins involved in intracellular Ca2+ 
handling in addition to the control of IP3R1 permeability.  
 
DISCUSSION 
Several reports have demonstrated the role of [Ca2+]ER in the resistance to proapoptotic stimuli and 
increased proliferation, two major hallmarks of cancer cells [26, 27]. In LNCaP cells, AD for 96h 
has been shown to induce neuroendocrine differentiation associated with a reduction in [Ca2+]ER. 
This observation was attributed to a decreased expression of SERCA2b and of the luminal Ca2+-
binding/storage chaperone protein calreticulin and was correlated with a decrease in sensitivity to 
thapsigargin and TNF-α [28]. In our experiments, we confirmed the decrease in [Ca2+]ER after AD 
but expression levels of SERCA2b and calreticulin were not modified. This apparent discrepancy 
could be attributed to the fact that in our study, AD was maintained for only 48h. The TRPM8 
expression was however strongly decreased and we also observed that basal Ca2+ influx through the 
plasma membrane was diminished after AD. This observation could explain the decrease in 
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[Ca2+]ER. Since expression of TRPM8 is known to be dependent of androgen receptor activation 
[16], we measured basal Ca2+ influx after siRNA-mediated TRPM8 depletion. It was decreased in 
TRPM8-depleted cells suggesting that it was, at least partially, localized in the plasma membrane. 
However, neither thapsigargin-induced Ca2+ release nor SOCE were modified by repression of 
TRPM8. We therefore conclude that TRPM8 repression and decrease in basal Ca2+ influx after AD 
were not related to the decrease in [Ca2+]ER. As expected, AD induced-TRPM8 decrease or siRNA-
mediated TRPM8 depletion decreased Ca2+ entry. However, they did not modify resting cytosolic 
[Ca2+], suggesting that their effects on Ca2+ entry is compensated by the activity of transporters 
allowing fluxes of Ca2+ out of the cells or into the ER. 
As mentioned above, phosphorylated IP3R1 was reported as an ER leak channel in mouse 
embryonic fibroblasts cells [12]. We therefore measured the expression and the phosphorylation of 
IP3R1 in AD conditions. Expression was increased by only 50% but phosphorylation on Ser-1716 
increased 3-fold after AD for 48h. Inhibiting PKA-dependent phosphorylation of IP3R1S1716 by 
competition with TAT-IP3R1S1716 abolished the effect of AD on [Ca2+]ER. This underpins the 
concept that beside its role in response to agonists, IP3R1 also constitutes in LNCaP cells an ER 
Ca2+ leak channel that is modulated by AD-dependent phosphorylation. In those cells, IP3R1 could 
therefore regulate [Ca2+]ER at rest. Inhibition of PKA by H89 also abolished AD-dependent decrease 
in [Ca2+]ER but also dramatically increased [Ca2+]ER in the presence of androgen. This could be due 
to the higher efficiency of H89 to reduce IP3R1 phosphorylation in comparison with TAT-
IP3R1S1716 (Fig. 5B and D). However, we cannot exclude an alternative pathway connecting PKA 
and [Ca2+]ER. 
Our results also clearly show that AD-dependent phosphorylation of IP3R1 is an important 
mediator of androgen resistance in PCa cells. Indeed, inhibition of IP3R1 phosphorylation with H89 
or TAT-IP3R1S1716 dramatically increased sensitivity to AD in LNCaP cells. Interestingly, this 
effect was seriously decreased after pretreatment with thapsigargin, indicating that the effect of 
PKA on AD-induced cell death is dependent on the Ca2+ content in the ER. The role of [Ca2+]ER in 
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androgen resistance was also confirmed by the fact that SERCA2b overexpression limited the effect 
of AD on Ca2+ store content and increased AD-induced apoptosis. Therefore, we show for the first 
time that survival of PCa cells in response to androgen removal is dependent on the (partial) 
depletion of their Ca2+ stores. 
It has been reported that PKA is overexpressed in PCa and constitutes a marker of poor prognosis 
[7]. Moreover, PKA hyperactivity could contribute to resistance of PCa cells to AD [29]. Our 
results suggest that IP3R1 phosphorylation by PKA could explain the decreased AD-induced cell 
death in HRPCa. Targeting the PKA-IP3R1 pathway could therefore constitute an interesting 
strategy to restore sensitivity to AD in HRPCa. 
Since AD itself induced phosphorylation on the PKA consensus site IP3R1S1716, we suggest that, 
beside its proapoptotic effect, AD concomitantly triggers a prosurvival pathway. Bagchi et al. 
showed that androgen stimulation induced PKA activation by increasing cAMP production [30]. 
This result is apparently contradictory to our data but it is noteworthy that in contrast to our 
experimental design (48 h AD), Bagchi et al. investigated short-term (10 min) effect of androgen on 
PKA-related pathways. Furthermore, prolonged AD treatment has been noticed to increase the 
expression of different catalytic subunits of PKA in LNCaP cells [31]. 
In a previous study, we showed that AD induced autophagy in LNCaP cells and that this process in 
turn inhibited AD-triggered cell death [22]. Therefore, we have investigated in the present study 
whether IP3R1S1716 phosphorylation and Ca2+ store depletion could be intermediates between AD 
and autophagy. Our data showed that inhibition of IP3R1S1716 phosphorylation does not interfere 
with AD-induced autophagy. Moreover, siRNA-mediated inhibition of autophagy has no effect on 
[Ca2+]ER. This suggests that AD-induced autophagy and AD-induced IP3R1S1716 phosphorylation 
constitute two independent mechanisms of resistance to AD. 
In conclusion, we show that phosphorylation of IP3R1 on a PKA consensus site modulates [Ca2+]ER 
and renders LNCaP cells more resistant to AD-induced apoptosis. This demonstrates that the 
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common anti-prostate cancer strategy consisting in androgen removal could interfere with ER Ca2+ 
homeostasis, highlighting the role of ER Ca2+ in the mechanisms of cancer aggressiveness. 
 
MATERIALS AND METHODS 
Cell culture and reagents 
LNCaP cells (American Type Culture Collection,	  Manassas, VA, USA, CRL-1740) were grown at 
37°C in an humidified atmosphere of 5% CO2–95% air in RPMI 1640 (Gibco Invitrogen, Carlsbad, 
CA, USA, 52400) supplemented with 10% fetal calf serum, 100 IU/ml penicillin (Gibco, 10270) 
and 100 µg/ml streptomycin (Gibco, 15140). Cells were cultured up to passage 30. Analysis of the 
effect of androgen deprivation was performed by culturing cells for 2 days in RPMI 1640 medium 
supplemented with charcoal-treated FCS (Gibco, 12676) for serum steroid hormone removal (-
R1881 condition). As control condition, the synthetic agonist of the androgen receptor (AR), 
methyltrienolone (R1881), was added to the medium at 0.2 nM (+R1881 condition). H89 (Sigma-
Aldrich, Saint Louis, MO, B1427) was used at 10 µM, thapsigargin (Sigma-Aldrich, T9033) at 0.5 
and 1 µM, ionomycin (Invitrogen, Carlsbad, CA, USA, I24222) at 10 µM. Xestospongin B  was 
purified from Xestospongia exigua as previously described [32]. The synthetic peptide TAT-
IP3R1S1716 (NH2-RKKRRQRRRGGRPSGRRESLTSFGNG-COOH) was obtained from 
ThermoFisher Scientific (Waltham, MA, USA) and used at 80 µM. 
 
siRNA transfection 
The siRNA targeting TRPM8 mRNA (siTRPM8; 5’-GCAAACUGGUUGCGAACUU-3’) as well 
as the non-silencing control siRNAs (siUNR) pool were purchased from Thermo Fisher Scientific 
(Lafayette, CO, USA). LNCaP cells were transfected using DharmaFECT reagent (Thermo Fisher 
Scientific, T-2002-03) according to the manufacturer’s instructions. Twenty-four hours later, cells 
were plated on six-well plates and after 48 additional hours subjected to AD treatment. Four days 
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after transfection, efficiency of siRNA-mediated depletion of the TRPM8 mRNA was assessed by 
RT-qPCR. 
 
SERCA2b transfection 
LNCaP cells, seeded in six-well culture plates until ~80% confluence, were co-transfected with a 
plasmid coding a DsRed fluorescent protein and an empty plasmid or a plasmid coding for 
SERCA2b using Lipofectamine reagent (Invitrogen, 11668-019) according to manufacturer’s 
instructions. After 24 hours, cells were plated on six-well plates and 48 hours later, were subjected 
to AD treatment during 2 at 3 days. 
 
Quantitative RT-PCR 
LNCaP mRNAs were extracted with Trizol reagent (Invitrogen). Gene-specific PCR primers were 
designed using Primer3 and purchased from Eurogentec (Seraing, Belgium). Primer sequences are 
given table 1. The β2-microglobulin was used as housekeeping gene. Quantitative RT-PCR was 
performed using 5 µL of cDNA, 12.5 µL of SYBRGreen Mix (Bio-Rad, Hercules, CA, USA) and 
300 nM of each primer in a total reaction volume of 25 µL. The reaction was initiated at 95 °C for 3 
min, followed by 40 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C for 1 min, and 
extension at 72 °C for 10 s. Data were recorded on a MyiQ qPCR detection system (Bio-Rad), and 
cycle threshold (Ct) values for each reaction were determined using analytical software from the 
same manufacturer. Each cDNA was amplified in duplicate, and Ct values were averaged for each 
duplicate. The average Ct value for β2-microglobulin was subtracted from the average Ct value for 
the gene of interest. This ∆Ct value obtained in –R1881 condition or in siRNA-TRPM8 silenced 
LNCaP was then subtracted from the ∆Ct value obtained in control conditions (+R1881 or siUNR 
in +R1881 condition) giving a ∆∆Ct value. As amplification efficiencies of the genes of interest and 
β2-microglobulin were comparable, the amount of mRNA, normalized to β2-microglobulin, was 
given by the relation 2-∆∆Ct. 
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Immunoblotting 
Cells were harvested by scraping in PBS and re-suspended in lysis buffer containing 20 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mM phenylmethanesulfonylfluoride 
and 1 µg/mL leupeptin. Extracts were diluted in a mix of LDS Sample Buffer and Sample Reducing 
Agent (NuPAGE®, Invitrogen, NP0007 and NP0009) and heated at 95°C for 3 min. Samples were 
electrophoresed on 4-12% or 12% SDS-polyacrylamide gels (Invitrogen, NP0321BOX and 
NP0341BOX) and transferred onto nitrocellulose membranes (Biorad, 162-0097). The blots were 
saturated in TBS-T buffer (20 mM Tris, 137 mM NaCl, 0.05% Tween 20, pH 7.6) containing 5% 
skimmed milk for 1 h at room temperature and incubated overnight at 4°C with primary antibodies: 
anti-TRPM8 (Abcam, Cambridge, UK, ab3243, dilution 1:10,000), and  anti-phospho-IP3RS1756 
(Cell Signaling Technology, Beverly, MA, USA, 3760; recognizing human IP3R1 phosphorylated 
on Ser-1716), anti-IP3R1 (Cell Signaling Technology, 8568), anti-LC3 (Cell Signaling Technology, 
3868) all used at a dilution of 1:1000. Immunodetection of β-actin with monoclonal anti-actin 
antibody (Sigma-Aldrich, A5441) was used as loading control (dilution 1:10,000). After incubation 
with appropriate secondary antibodies coupled to peroxidase, peroxidase activity was detected with 
ECL Prime (GE Healthcare, Uppsala, Sweden, RPN2236) on ECL hyperfilm. Immunoblots were 
quantified using the ImageMaster densitometry program. 
 
Calcium measurements 
Cells were plated on glass coverslips, subjected to various treatments during 2 days and then 
incubated for 1 hour at room temperature with 1 µM Fura-2/AM (Calbiochem, Camarillo, CA, 
USA) in Krebs-HEPES buffer containing 11.5 mM HEPES, 135.5 mM NaCl, 5.9 mM KCl, 1.8 mM 
CaCl2, 1.2 mM MgCl2, 11.5 mM D-glucose, pH 7.4. After rinsing, measurements were then 
realized in Krebs-HEPES buffer without CaCl2 and supplemented with 0.2 mM EGTA. Coverslips 
were mounted in a heated (37 °C) microscope chamber. Cells were alternately excited (0.5 Hz) at 
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340 and 380 nm using a Lambda DG-4 Ultra High Speed Wavelength Switcher (Sutter Instrument, 
Novato, CA, USA) coupled to a Zeiss Axiovert 200 M inverted microscope (Zeiss Belgium, 
Zaventem, Belgium). Images were acquired with a Zeiss Axiocam camera coupled to a 510-nm 
emission filter and analyzed with Axiovision software. Cytosolic free Ca2+ concentration ([Ca2+]c) 
was evaluated from the ratio of fluorescence emission intensities excited at the two wavelengths 
using the Grynkiewicz equation [33]. 
The progressive fluorescence quenching due to the influx of 100 µM Mn2+ (Sigma-Aldrich) was 
monitored by measurement of Fura-2/AM emission intensity (excitation at 360 nm). The slope of 
the Mn2+-induced fluorescence quenching was measured on the first 30 seconds after adding Mn2+. 
 
Flow cytometry 
Simultaneous detection of mitochondrial membrane potential (ΔΨm) dissipation and plasma 
membrane permeabilization was determined by staining with 40 nM ΔΨm-sensitive fluorochrome 
DiOC6(3) (Molecular Probes-Invitrogen, Carlsbad, CA, USA, D273) and 1 µg/ml vital dye 
propidium iodide, PI (Sigma-Aldrich, P1304MP). All PI+ events have been considered at DiOC 
low. Cytofluorometric analyses were performed on a FACSCalibur equipped with CellQuest Pro 
software (Becton Dickinson, Franklin Lakes, NJ, USA). 
 
GFP-LC3 transfection and imaging 
LNCaP cells, seeded in six-well culture plates until ~80% confluence, were transfected with a 
plasmid coding for GFP-LC3 using Lipofectamine reagent. After 24 hours, cells were plated on 
glass coverslips and 48 hours later, were subjected to various treatments during 2 days. GFP 
fluorescence was analyzed on an inverted Axiovert 200 microscope (Zeiss) using FITC excitation 
and emission wavelengths (100×, NA 1.4, oil immersion). Images were acquired with a Zeiss 
Axiocam and analyzed by the Zeiss Axiovision software. 
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Statistical Analysis 
Data are presented as means ± SD. Student's t-test and two-way ANOVA were used to determine 
statistical significance when appropriate. 
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FIGURE LEGENDS 
Figure 1. Intracellular Ca2+ homeostasis alterations after androgen deprivation. (A) LNCaP cells 
cultured for 48 h in the presence of 0.2 nM R1881 (+R1881 condition) or in its absence (-R1881 
condition) were loaded with Fura-2/AM and stimulated with 1 µM thapsigargin in the absence of 
extracellular Ca2+. After 5 min, Ca2+ was reintroduced in the external medium to evaluate SOCE 
amplitude. Representative thapsigargin-evoked changes in [Ca2+]c are presented for both conditions. 
(B) Bar histogram showing in both conditions the [Ca2+]c measured in Fura-2/AM stained LNCaP 
cells first in the absence of extracellular Ca2+, then after addition of 1 µM thapsigargin (Thaps) and 
finally after addition of 1.8 mM extracellular Ca2+ (SOCE) (means ± S.D. of five independent 
experiments, ** p < 0.01, *** p < 0.001). (C) By measurement of Fura-2/AM emission intensity 
(excitation at 360 nm), the progressive fluorescence quenching due to the influx of Mn2+, taken as a 
surrogate of Ca2+, was monitored in LNCaP cells in both conditions. The slope of the Mn2+-induced 
fluorescence quenching was decreased more than twice in the –R1881 condition, revealing that the 
calcium influx through the cell membrane was strongly decreased after AD (means ± S.D. of three 
independent experiments). 
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Figure 2. Bar histogram showing the relative mRNA expression of genes involved in calcium 
homeostasis after AD in LNCaP cells. Two days after AD treatment, total RNA was extracted and 
reverse-transcribed. qPCR was performed with specific primers. The mRNA expression of each 
gene was normalized to β2-microglobulin expression (means ± S.D. of four independent 
experiments, ** p < 0.01, *** p < 0.001). 
 
Figure 3. Role of TRPM8 in LNCaP cells. (A, B) LNCaP cells were transfected with a siRNA 
targeting TRPM8 mRNA (siTRPM8) or with a non-silencing control siRNAs (siUNR) pool and 
then cultured in the presence of 0.2 nM R1881. The silencing of TRPM8 was proved by RT-qPCR 
(A) and immunoblot (B). β-actin was used as loading control. Four days after transfection, total 
RNA was extracted and reverse-transcribed. qPCR was performed with specific primers. The results 
are expressed as the level of TRPM8 expression normalized to β2-microglobulin expression (means 
± S.D. of three independent experiments, *** p < 0.001). (B) Bar histogram showing in siUNR and 
siTRPM8 conditions the intracellular Ca2+ concentrations measured in Fura-2/AM stained LNCaP 
cells first in the absence of extracellular Ca2+ (Rest), then after addition of 1 µM thapsigargin 
(Thaps) and finally after addition of 1.8 mM extracellular Ca2+ (SOCE) (means ± S.D. of three 
independent experiments). (C) Mn2+-induced fluorescence quenching of Fura-2/AM in LNCaP cells 
four days after transfection with siUNR or siTRPM8 (means ± S.D. of three independent 
experiments, * p < 0.05).  
 
Figure 4. Phosphorylation of IP3R1 on Ser-1716 after AD. (A) Immunoblot analysis of the 
expression of IP3R1 and of its phosphorylation on Ser-1716 in LNCaP cells cultured for 48 h in the 
presence of 0.2 nM R1881 (+R1881 condition) or in its absence (-R1881 condition). β-actin was 
used as a loading control. Data presented are representative of seventeen independent experiments. 
(B) Bar histogram showing phosphorylation and total expression level of IP3R1 in both conditions 
(means ± S.D. of seventeen independent experiments, ** p < 0.01, *** p < 0.001). 
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Figure 5. Involvement of IP3R1 phosphorylation in Ca2+ homeostasis alterations induced by AD. 
(A) Bar histogram showing the thapsigargin-induced Ca2+ release in the absence of extracellular 
Ca2+ measured in Fura-2/AM-loaded LNCaP cells cultured in the presence or in the absence of 0.2 
nM R1881 and pretreated or not with 2 µM Xestospongin B (means ± S.D. of three independent 
experiments, * p < 0.05). (B) Immunoblot analysis of the expression of IP3R1 and of its 
phosphorylation on Ser-1716 in LNCaP cells cultured in the presence or in the absence of 0.2 nM 
R1881 and treated for 48 h with 80 µM cell-permeant TAT-peptide (TAT-IP3R1S1716) containing 
the Ser-1716 consensus phosphorylation sequence or with 10 µM PKA inhibitor H89 . β-actin was 
used as a loading control. Data presented are representative of three independent experiments. (C 
and D) Quantification of data presented in A and B (means ± S.D. of three to seven independent 
experiments, ** p < 0.01, *** p < 0.001). (E) Bar histograms showing the effects of TAT-
IP3R1S1716 on the [Ca2+]c measured in Fura-2/AM-loaded LNCaP cells cultured in the presence or in 
the absence of 0.2 nM R1881 after addition of 10 µM ionomycin in the absence of extracellular 
Ca2+ (means ± S.D. from 6 to 7 independent experiments, * p < 0.05). (F) Bar histograms showing 
the effects of H89 on the [Ca2+]c measured in Fura-2/AM-loaded LNCaP cells cultured in the 
presence or in the absence of 0.2 nM R1881 after addition of 10 µM ionomycin in the absence of 
extracellular Ca2+ (means ± S.D. from 5 to 6 independent experiments, * p < 0.05, *** p < 0.001).  
 
Figure 6. Inhibition of IP3R1 phosphorylation sensitizes LNCaP cells to AD. (A) Cytofluorimetric 
assessment of the effects of AD in the absence or in the presence of  80 µM TAT-IP3R1S1716 on 
apoptosis-associated mitochondrial transmembrane potential (ΔΨm) dissipation and plasma 
membrane permeabilization. Cells were treated for 72 h and then labelled with the ΔΨm-sensitive 
probe DiOC6(3) and with propidium iodide (PI). Representative dot plots recorded upon AD 
treatment in the absence and in the presence of TAT-IP3R1S1716 are shown. Numbers in each 
quadrant indicate the percentage of cells. (B) Quantification of data illustrated in A as well as of 
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cells cultured in the presence of R1881 and similarly treated. White and black columns represent 
percentages of cells exhibiting ΔΨm loss alone (DiOC6(3)low) or in association with plasma 
membrane breakdown (PI+), respectively. Data are presented as means ± S.D. of three independent 
experiments (* p < 0.05). (C and D) Similar experiments were performed in the absence or in the 
presence of 10 µM H89 for 72 h. Effects of thapsigargin (Thaps) were also monitored. Data are 
presented as means ± S.D. of three independent experiments (* p < 0.05, *** p < 0.001).   
 
Figure 7.  SERCA2b overexpression prevents Ca2+ store depletion and promotes cell death after 
AD. (A) LNCaP cells cultured in the presence or in the absence of 0.2 nM R1881 were transfected 
with a control plasmid or a plasmid encoding SERCA2b and with a dsRed expressing plasmid 
allowing detection of transfected cells. Cells were loaded with Fura-2/AM and stimulated with 10 
µM ionomycin in the absence of extracellular Ca2+. Bar histogram showing the effects of SERCA2b 
overexpression on the [Ca2+]c in dsRed-positive cells after addition of ionomycin (means ± S.D. 
from 4 to 6 independent experiments, *** p < 0.001). (B) Cytofluorimetric assessment of the effects 
of AD in dsRed-positive cells on apoptosis-associated mitochondrial transmembrane potential 
(ΔΨm) dissipation. Transfected LNCaP cells were cultured for 72 h in the presence or in the absence 
of 0.2 nM R1881 and then labelled with the ΔΨm-sensitive probe DiOC6(3). Bar histogram shows 
percentages of dsRed-positive cells exhibiting ΔΨm loss for each condition. Data are presented as 
means ± S.D. of three independent experiments (* p < 0.05, ** p < 0.01). 
 
Figure 8. [Ca2+]ER and autophagy. (A) Immunoblot analysis assessing LC3-II protein levels after 48 
h AD treatment in with the absence or presence of 10 µM H89. E64d (10 µg/ml) and pepstatin A 
(10 µg/ml) were added during the treatment. β-actin was used as a loading control. Immunoblots are 
representative of three independent experiments. (B) Quantification of data illustrated in A. Data 
are presented as means ± S.D. of at least three independent experiments (* p < 0.05). (C) LNCaP 
cells were transfected with a plamid encoding a GFP-LC3 fusion protein. Bar histogram showing 
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the number of cells exhibiting more than 10 fluorescent dots after treatment by 10 µM H89 for 48 h 
in the presence or in the absence of 0.2 nM R1881 (means ± SD of three independent experiments, 
** p < 0.01, *** p < 0.001). (D) LNCaP cells were transfected with a pool of 4 siRNAs targeting 
Atg5 mRNA (siATG5) or with a non-silencing control siRNAs (siUNR) pool and then cultured in 
the presence or in the absence of 0.2 nM R1881 for 48 h. LNCaP cells were loaded with Fura-2/AM 
and stimulated with 1 µM thapsigargin in the absence of extracellular Ca2+. Bar histogram showing 
thapsigargin-evoked changes in [Ca2+]c for each condition (means ± S.D. of three independent 
experiments, *** p < 0.001). 
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